Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings

BACKGROUND: Tumor mutation burden (TMB), a biomarker for immune checkpoint inhibitor (CPI) response, is reported by both blood- and tissue-based next-generation sequencing (NGS) vendors. However, the agreement between TMB from blood (bTMB) and tissue (tTMB) in real-world settings, both in absolute v...

Descripción completa

Detalles Bibliográficos
Autores principales: Sturgill, Emma G, Misch, Amanda, Jones, Carissa C, Luckett, Daniel, Fu, Xiaotong, Schlauch, Dan, Jones, Suzanne F, Burris, Howard A, Spigel, David R, McKenzie, Andrew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Cancer Diagnostics and Molecular Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914506/
https://www.ncbi.nlm.nih.gov/pubmed/35274716
http://dx.doi.org/10.1093/oncolo/oyab064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914506/
https://www.ncbi.nlm.nih.gov/pubmed/35274716
http://dx.doi.org/10.1093/oncolo/oyab064

Ejemplares similares